Close Menu
September 25, 2019
Sponsored by
HalioDx

Biomarker Evaluation for CAR T-Cell Therapy: Impact on Drug Development

Genome Webinar

Vice President of Translational Medicine
Kite, a Gilead Company

CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. While this approach has demonstrated impressive results for some patients, there are still challenges such as toxicity and difficulty in predicting which patients will respond.

The immune microenvironment is one of the factors that influences clinical outcomes, so identifying immune biomarkers is critical to maximizing the benefits of CAR T-cell therapy.

During this webinar, Adrian Bot, Vice President of Translational Medicine at Kite, a Gilead Company, explains how biomarker evaluation for CAR T-cell therapy can elucidate the mechanism of action and impact drug development.

This webinar also includes a brief overview of HalioDx's Immunogram platform and how it can provide meaningful and actionable data through biomarker testing.

Viewers of this webinar will learn:

  • How CAR T-cell therapy fights cancer cells and the associated mechanism of action.
  • Why evaluating immune biomarkers in CAR T-cells is crucial.
  • How biomarker evaluation can impact immunotherapy drug development.
Sponsored by
Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.